Clinical characteristics of responders to intravitreal bevacizumab in central serous chorioretinopathy patients.

about

Factors affecting the visual outcome in acute central serous chorioretinopathy.Visual and Anatomical Outcomes of Spironolactone Therapy in Patients with Chronic Central Serous Chorioretinopathy.

P2860

Q37723609-48B08DF6-6CCB-4CE2-97FE-1C9D701BDE7D Q41112838-B59FB63B-8EA4-47CC-8A8E-F0F6EDDDB2F8

P2860

Clinical characteristics of responders to intravitreal bevacizumab in central serous chorioretinopathy patients.

Item

http://www.wikidata.org/entity/Q35749002

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Clinical characteristics of re ...... us chorioretinopathy patients.

@ast

Clinical characteristics of re ...... us chorioretinopathy patients.

@en

type

Item

label

Clinical characteristics of re ...... us chorioretinopathy patients.

@ast

Clinical characteristics of re ...... us chorioretinopathy patients.

@en

prefLabel

Clinical characteristics of re ...... us chorioretinopathy patients.

@ast

Clinical characteristics of re ...... us chorioretinopathy patients.

@en

P1476

Clinical characteristics of re ...... ous chorioretinopathy patients

@en

P2093

C S Lee

http://www.w3.org/2001/XMLSchema#string

G A Kim

http://www.w3.org/2001/XMLSchema#string

S C Lee

http://www.w3.org/2001/XMLSchema#string

S S Kim

http://www.w3.org/2001/XMLSchema#string

P2860

Two-year results of reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy.

A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema

Punctate hyperfluorescent spots associated with central serous chorioretinopathy as seen on indocyanine green angiography.

The effect of intravitreal bevacizumab in patients with acute central serous chorioretinopathy.

Minimal effects of VEGF and anti-VEGF drugs on the permeability or selectivity of RPE tight junctions.

Oral mifepristone for chronic central serous chorioretinopathy.

Type A behavior and central serous chorioretinopathy.

Intravitreal bevacizumab for iatrogenic choroidal neovascularization due to laser photocoagulation in central serous chorioretinopathy.

Central serous chorioretinopathy and glucocorticoids.

Choroidal capillary and venous congestion in central serous chorioretinopathy.

P2888

eye.2015.58

P304

732-40; quiz 741

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/EYE.2015.58

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Tyler Hyungtaek Rim

Suk Ho Byeon

Hyoung Jun Koh

P577

2015-05-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25952951

http://www.w3.org/2001/XMLSchema#string

P921

bevacizumab

P932

4469674

http://www.w3.org/2001/XMLSchema#string

Clinical characteristics of responders to intravitreal bevacizumab in central serous chorioretinopathy patients.

about

P2860

P2860

Clinical characteristics of responders to intravitreal bevacizumab in central serous chorioretinopathy patients.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932